Overview

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
A 26 week maintenance study of CDP870 in Crohn's disease
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Certolizumab Pegol